ACELYRIN, INC. Common Stock (SLRN) - Total Assets
Based on the latest financial reports, ACELYRIN, INC. Common Stock (SLRN) holds total assets worth $436.50 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SLRN net asset value for net asset value and shareholders' equity analysis.
ACELYRIN, INC. Common Stock - Total Assets Trend (2021–2024)
This chart illustrates how ACELYRIN, INC. Common Stock's total assets have evolved over time, based on quarterly financial data.
ACELYRIN, INC. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
ACELYRIN, INC. Common Stock's total assets of $436.50 Million consist of 97.9% current assets and 2.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.0% |
| Accounts Receivable | $30.23 Million | 6.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how ACELYRIN, INC. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of ACELYRIN, INC. Common Stock.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ACELYRIN, INC. Common Stock's current assets represent 97.9% of total assets in 2024, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 15.0% of total assets in 2024, down from 99.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 6.2% of total assets.
ACELYRIN, INC. Common Stock Competitors by Total Assets
Key competitors of ACELYRIN, INC. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
ACELYRIN, INC. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.43 | 13.27 | 10.06 |
| Quick Ratio | 18.43 | 13.11 | 10.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $406.19 Million | $641.70 Million | $297.39 Million |
ACELYRIN, INC. Common Stock - Advanced Valuation Insights
This section examines the relationship between ACELYRIN, INC. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.56 |
| Latest Market Cap to Assets Ratio | 0.47 |
| Asset Growth Rate (YoY) | -33.9% |
| Total Assets | $491.14 Million |
| Market Capitalization | $229.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values ACELYRIN, INC. Common Stock's assets below their book value (0.47x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ACELYRIN, INC. Common Stock's assets decreased by 33.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ACELYRIN, INC. Common Stock (2021–2024)
The table below shows the annual total assets of ACELYRIN, INC. Common Stock from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $491.14 Million | -33.87% |
| 2023-12-31 | $742.69 Million | +123.06% |
| 2022-12-31 | $332.96 Million | +225.46% |
| 2021-12-31 | $102.30 Million | -- |
About ACELYRIN, INC. Common Stock
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorp… Read more